Here are five takeaways:
1. The procedure involves using an implant one-third the size of traditional shoulder implants and requires less bone removal.
2. Catalyst Orthoscience’s implant is designed for more accurate placement and to give patients quicker recovery times.
3. The device is designed to allow patients to stop using opioids three to four days after surgery and to cut their hospital stays in half.
4. The CSR shoulder earned FDA approval in 2016. Since then, hundreds of surgeries have been performed using the device.
5. Catalyst Orthoscience was founded in 2014 by orthopedic surgeon Steven Golderberg, MD.
More articles on devices and implants:
More than just outcomes — Predictive analytics provide support through the surgical continuum
Moving from art to science brings new possibilities to spine surgery
Globus Medical, SeaSpine & more: 5 device company notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.